Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PA-8是一种小分子的的 PACAP I 型(PAC1)受体拮抗剂,有 选择性、有效性和口服活性。PA-8抑制PACAP 诱导的CREB 在PAC1-受体上的磷酸化,但对VPAC11或VPAC2受体无抑制作用。PA-8也抑制pacap 诱导的体外cAMP 水平升高(IC50 = 2 nM)和体内鞘内注射后pacap 诱导的厌恶反应和机械异位性痛。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 185 | 现货 | ||
5 mg | ¥ 413 | 现货 | ||
10 mg | ¥ 747 | 现货 | ||
25 mg | ¥ 1,570 | 现货 | ||
50 mg | ¥ 2,730 | 现货 | ||
100 mg | ¥ 4,130 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 455 | 现货 |
产品描述 | PA-8 is a small molecule receptor antagonist for PACAP Type I (PAC1) that is selective, effective, and orally active. PA-8 inhibits PacAP-induced CREB phosphorylation at PAC1- receptors, but does not inhibit VPAC1- or vpac2 receptors. PA-8 also inhibited PacAP-induced elevation of cAMP levels in vitro (IC50 = 2 nM) and PacAP-induced aversive response and mechanical atopic pain after intrathecal injection in vivo. |
靶点活性 | cAMP:2 nM |
体外活性 | In PAC1/CHO cells, PA-8 (10 pM to 10 nM; 30 minutes) dose dependently inhibits PACAP (1 nM)-induced CREB phosphorylation. In VPAC1/CHO and VPAC2/CHO cells, PACAP (1 nM) also induced CREB phosphorylation; however, PA-8 (10 pM to 10 nM) does not inhibit PACAP (1 nM)-induced CREB phosphorylation [1] . |
体内活性 | PA-8 (100 pmol/5 μL; intrathecal injection; once; male ddY mice) treatment inhibits PACAP-induced aversive responses and mechanical allodynia in vivo [1] . PA-8 (3-30 mg/kg, p.o.) treatment results in the dose-dependent attenuation of the second phase of formalin-induced nociceptive responses. PA-8 also inhibits c-fos upregulation in the ipsilateral dorsal horn of the spinal cord [2] . Animal Model: Male ddY mice (6 weeks old) injected with PACAP (100 pmol) [1] Dosage: 100 pmol/5 μL Administration: Intrathecal injection; once Result: Inhibited PACAP-induced aversive responses and mechanical allodynia in vivo. |
分子量 | 342.35 |
分子式 | C17H18N4O4 |
CAS No. | 878437-15-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 22.5 mg/mL (65.7 mM), Sonication and heating to 60℃ are recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.921 mL | 14.6049 mL | 29.2099 mL | 73.0247 mL |
5 mM | 0.5842 mL | 2.921 mL | 5.842 mL | 14.6049 mL | |
10 mM | 0.2921 mL | 1.4605 mL | 2.921 mL | 7.3025 mL | |
20 mM | 0.146 mL | 0.7302 mL | 1.4605 mL | 3.6512 mL | |
50 mM | 0.0584 mL | 0.2921 mL | 0.5842 mL | 1.4605 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
PA-8 878437-15-1 GPCR/G Protein PACAP PA 8 PA8 Inhibitor inhibitor inhibit